SCHEDULE: ARK Investment Management and Catherine Wood Disclose 6.32% Stake in Arcturus Therapeutics
Ownership Disclosure
ARK Investment Management LLC and Catherine D. Wood have disclosed a 6.32% beneficial ownership stake in Arcturus Therapeutics Holdings Inc., holding 1,715,040 shares of common stock.
Summary
- ARK Investment Management LLC and Catherine D. Wood jointly filed an Amendment No. 8 to Schedule 13G regarding their beneficial ownership in Arcturus Therapeutics Holdings Inc.
- As of June 30, 2025, the reporting persons collectively beneficially own 1,715,040 shares of Arcturus Therapeutics Holdings Inc. Common Stock.
- This ownership represents 6.32% of the class of securities.
- ARK Investment Management LLC holds sole voting and sole dispositive power over all 1,715,040 shares.
- Catherine D. Wood holds shared voting and shared dispositive power over all 1,715,040 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
- ARK Genomic Revolution ETF, a series of a Delaware statutory trust, is identified as a client of ARK Investment Management LLC with an interest exceeding 5% in the reported securities.
Sentiment
Score: 5
Explanation: This is a factual ownership disclosure filing, which inherently carries a neutral sentiment regarding the company's operational performance or future prospects. The presence of a notable institutional investor could be interpreted positively by some, but the filing itself is purely informational.
Positives
- A significant beneficial ownership stake (6.32%) by a prominent investment firm like ARK Investment Management and its CEO, Catherine D. Wood, may signal confidence in Arcturus Therapeutics Holdings Inc.
Industry Context
This filing reflects continued or new interest from a major investment firm known for its focus on disruptive innovation, particularly in the biotechnology and healthcare sectors. ARK's investment in Arcturus Therapeutics aligns with its strategy of identifying companies at the forefront of scientific advancement, which could be seen as a validation of Arcturus's potential within the broader biotech industry.
Stakeholder Impact
- Shareholders may view the significant stake held by ARK Investment Management and Catherine D. Wood as a positive signal, potentially increasing investor confidence and interest in Arcturus Therapeutics Holdings Inc.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which required the filing of this statement, indicating the beneficial ownership percentage. |
| 07/30/2025 | Date the Schedule 13G Amendment No. 8 was signed and filed. |
Keywords
Arcturus Therapeutics, ARK Investment Management, Catherine D. Wood, Biotechnology, Pharmaceuticals, Investment, Ownership Disclosure, Institutional Investor, Common Stock, SEC Filing, Schedule 13G
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.